A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Bristol-Myers Squibb
Bristol-Myers Squibb
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
7 Hills Pharma, LLC
Pfizer
Bristol-Myers Squibb
Hackensack Meridian Health
ModernaTX, Inc.
H. Lee Moffitt Cancer Center and Research Institute
Vivace Therapeutics, Inc
Bristol-Myers Squibb
University Hospital, Essen
Neonc Technologies, Inc.
Bristol-Myers Squibb
Big Ten Cancer Research Consortium
Sanofi